Gene Expression News and Research

RSS

Gene Expression is the process by which a gene gets turned on in a cell to make RNA and proteins. Gene expression may be measured by looking at the RNA, or the protein made from the RNA, or what the protein does in a cell.

BARDA awards Duke University $3.7M to develop diagnostic test for detecting radiation exposure

Duke University has received a $3.7 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop a rapid and accurate genomic-based diagnostic test that can determine if a person has been exposed to radiation from a dirty bomb or nuclear attack. In the event that all option years are exercised by the government, Duke University could receive up to $43.6 million from the contract.

21 Jan 2010

Gene study could result in personalized therapies for patients with deadly brain cancer

New findings by researchers at UNC Lineberger Comprehensive Cancer Center suggest that the most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is probably not a single disease but a set of diseases, each with a distinct underlying molecular disease process.

20 Jan 2010

TCGA study reveals four distinct molecular subtypes of GBM

The most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is not a single disease but appears to be four distinct molecular subtypes, according to a study by the Cancer Genome Atlas (TCGA) Research Network. The researchers of this study also found that response to aggressive chemotherapy and radiation differed by subtype.

20 Jan 2010

New pre-clinical data on RXi Pharmaceuticals' proprietary rxRNA compounds presented

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that new pre-clinical data using proprietary rxRNA™ compounds was presented at the Keystone Symposia’s RNA Silencing: Mechanism, Biology and Application held January 14-19 in Keystone, Colorado.

20 Jan 2010

HSF1A stimulates more protein chaperones and reduces protein misfolding

Scientists at Duke University Medical Center have found some compounds that improve a cell's ability to properly "fold" proteins and could lead to promising drugs for degenerative nerve diseases, including Huntington's disease, Alzheimer's disease and Parkinson's disease.

20 Jan 2010

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the “RNA Silencing: Mechanism, Biology, and Application” Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam’s therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington’s disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics.

20 Jan 2010

Preliminary data from Phase 1 study of Sangamo BioSciences' SB-728-T announced

Sangamo BioSciences, Inc. announced today that preliminary data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were presented on Friday, January 15, 2010 at the Keystone Symposium Session "HIV Biology and Pathogenesis."

20 Jan 2010

Leafy green vegetables, folate and multivitamins can prevent lung cancer in smokers

Leafy green vegetables, folate, and some multivitamins could serve as protective factors against lung cancer in current and former smokers, according to a study that is a first step in understanding a complex association.

19 Jan 2010

Research may pave for further studies on various human skin disorders

The leopard cannot change its spots, nor can the tiger change its stripes, but a new research report published in the January 2009 issue of the journal GENETICS tells us something about how cats end up with their spots and stripes

18 Jan 2010

Mutagenic drugs designed to kill viruses may make them stronger, says research

As the flu season continues in full-swing, most people can appreciate the need for drugs that stop viruses after they take hold in the body. Despite this serious need for new drugs, a team of researchers from the University of Texas at Austin raise serious concerns about an emerging strategy for stopping viral infections.

18 Jan 2010

Sirnaomics certifies polypeptide nanoparticle technology

Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has licensed a polypeptide nanoparticle technology invented by Professor A. James Mixson of University of Maryland Medical School.

18 Jan 2010

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

Regulus Therapeutics Inc. today announced that new pre-clinical data from multiple therapeutic programs were presented at the “RNA Silencing: Mechanism, Biology and Application” Keystone Symposium held January 14 – 19, 2010 in Keystone, Colorado. Regulus and its collaborators presented data showing microRNA target regulation by anti-miRs, as well as data from therapeutic programs focused on oncology, immune disease and hepatitis C virus (HCV) infection.

18 Jan 2010

Findings could pave way for new therapeutic approaches for Friedreich's ataxia

Elevated levels of DNA damage have for the first time been found in the cellular mitochondria and nuclei of patients with the inherited, progressive nervous system disease called Friedreich's ataxia (FRDA), says a multicenter research team led by an expert from the University of Pittsburgh Cancer Institute (UPCI).

18 Jan 2010

Researchers identify ways to predict patients with small-cell lung cancer

Researchers for TGen Clinical Research Services at Scottsdale Healthcare (TCRS) have identified a way to predict which patients with small-cell lung cancer may be resistant to first-line chemotherapy.

18 Jan 2010

Celgene acquires Gloucester Pharmaceuticals

Celgene Corporation today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

18 Jan 2010

Monsanto and Stokes Bio announce licensing agreement and R&D collaboration

Monsanto Company and Limerick-based biotechnology firm, Stokes Bio Limited, announced today that they have entered into a licensing agreement and R&D collaboration, which is expected to help accelerate the pace of new advancements in plant breeding.

13 Jan 2010

miRagen Therapeutics establishes SAB

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today the formation of the company’s world renowned Scientific Advisory Board (SAB). The SAB was established to provide miRagen with valuable guidance in developing an extensive pipeline of microRNA-based drugs and is comprised of leaders who are internationally recognized experts in their respective fields.

12 Jan 2010

Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics

Sangamo BioSciences, Inc. announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as well as the renewal of $3.0 million in funding for the Phase 2b trial by the Juvenile Diabetes Research Foundation International (JDRF).

11 Jan 2010

Inovio Biomedical expands existing license agreement with the University of Pennsylvania

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that it has expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide licenses for technology and intellectual property for novel DNA vaccines against pandemic influenza, Chikungunya, and foot-and-mouth disease.

11 Jan 2010

Illumina launches HumanOmniExpress BeadChip for GWAS

Illumina, Inc. today announced the HumanOmniExpress BeadChip (OmniExpress), the newest addition to the Omni family of microarrays for genome-wide association studies (GWAS).

From Illumina, Inc. 11 Jan 2010